Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARCT NASDAQ:ATHE NASDAQ:OKUR NASDAQ:TNXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$5.76-0.6%$6.93$5.50▼$24.17$163.53M2.37471,301 shs88,501 shsATHEAlterity Therapeutics$4.49+1.0%$4.70$2.66▼$5.89$39.78M0.2528,967 shs8,743 shsOKUROnKure Therapeutics$3.96+0.1%$4.27$1.91▼$5.38$159.98M0.27264,581 shs8,779 shsTNXPTonix Pharmaceuticals$9.85+3.6%$11.86$9.40▼$69.97$156.90M1.64458,931 shs140,549 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics+0.70%-2.36%-15.10%-32.83%-55.67%ATHEAlterity Therapeutics+1.10%-2.23%-6.03%+1.21%-13.95%OKUROnKure Therapeutics0.00%-8.56%-12.22%-25.05%+74.78%TNXPTonix Pharmaceuticals-4.33%-10.20%-25.41%-26.45%-77.69%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$5.76-0.6%$6.93$5.50▼$24.17$163.53M2.37471,301 shs88,501 shsATHEAlterity Therapeutics$4.49+1.0%$4.70$2.66▼$5.89$39.78M0.2528,967 shs8,743 shsOKUROnKure Therapeutics$3.96+0.1%$4.27$1.91▼$5.38$159.98M0.27264,581 shs8,779 shsTNXPTonix Pharmaceuticals$9.85+3.6%$11.86$9.40▼$69.97$156.90M1.64458,931 shs140,549 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics+0.70%-2.36%-15.10%-32.83%-55.67%ATHEAlterity Therapeutics+1.10%-2.23%-6.03%+1.21%-13.95%OKUROnKure Therapeutics0.00%-8.56%-12.22%-25.05%+74.78%TNXPTonix Pharmaceuticals-4.33%-10.20%-25.41%-26.45%-77.69%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARCTArcturus Therapeutics 2.64Moderate Buy$24.25321.37% UpsideATHEAlterity Therapeutics 2.40Hold$13.00189.86% UpsideOKUROnKure Therapeutics 2.00Hold$21.00430.97% UpsideTNXPTonix Pharmaceuticals 3.00Buy$24.00143.56% UpsideCurrent Analyst Ratings BreakdownLatest ATHE, TNXP, ARCT, and OKUR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/28/2026OKUROnKure Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)7/28/2026TNXPTonix Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)7/20/2026OKUROnKure Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$21.007/17/2026ARCTArcturus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026ATHEAlterity Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/13/2026TNXPTonix Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/30/2026ATHEAlterity Therapeutics JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$16.006/24/2026TNXPTonix Pharmaceuticals Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$26.006/24/2026TNXPTonix Pharmaceuticals Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/17/2026ATHEAlterity Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold6/16/2026ATHEAlterity Therapeutics LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.00(Data available from 7/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARCTArcturus Therapeutics$82.03M1.99N/AN/A$7.53 per share0.76ATHEAlterity TherapeuticsN/AN/AN/AN/A$3.10 per shareN/AOKUROnKure TherapeuticsN/AN/AN/AN/A$4.11 per shareN/ATNXPTonix Pharmaceuticals$13.11M11.98N/AN/A$19.17 per share0.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARCTArcturus Therapeutics-$65.78M-$2.81N/AN/AN/A-143.80%-36.55%-28.40%8/6/2026 (Confirmed)ATHEAlterity Therapeutics-$7.87MN/AN/AN/AN/AN/AN/AN/A8/28/2026 (Estimated)OKUROnKure Therapeutics-$59.52M-$4.33N/AN/AN/AN/A-61.02%-55.99%8/11/2026 (Estimated)TNXPTonix Pharmaceuticals-$124.02M-$14.36N/AN/AN/A-839.52%-67.65%-60.47%8/10/2026 (Estimated)Latest ATHE, TNXP, ARCT, and OKUR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026OKUROnKure Therapeutics-$0.58N/AN/AN/A$0.17 millionN/A8/10/2026Q2 2026ARCTArcturus Therapeutics-$1.07N/AN/AN/A$3.11 millionN/A8/10/2026Q2 2026TNXPTonix Pharmaceuticals-$2.6425N/AN/AN/A$7.72 millionN/A5/11/2026Q1 2026TNXPTonix Pharmaceuticals-$2.54-$2.93-$0.39-$2.93$6.13 million$6.88 million5/8/2026Q1 2026ARCTArcturus Therapeutics-$1.0320-$0.95+$0.0820-$0.95$6.30 million$2.06 million5/5/2026Q1 2026OKUROnKure Therapeutics-$0.7425-$1.11-$0.3675-$1.11$0.17 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARCTArcturus TherapeuticsN/AN/AN/AN/AN/AATHEAlterity TherapeuticsN/AN/AN/AN/AN/AOKUROnKure TherapeuticsN/AN/AN/AN/AN/ATNXPTonix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARCTArcturus TherapeuticsN/A6.316.31ATHEAlterity TherapeuticsN/A21.97N/AOKUROnKure TherapeuticsN/A13.7813.78TNXPTonix PharmaceuticalsN/A6.996.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARCTArcturus Therapeutics94.54%ATHEAlterity Therapeutics2.14%OKUROnKure Therapeutics90.98%TNXPTonix Pharmaceuticals82.26%Insider OwnershipCompanyInsider OwnershipARCTArcturus Therapeutics17.80%ATHEAlterity Therapeutics38.80%OKUROnKure Therapeutics2.17%TNXPTonix Pharmaceuticals2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARCTArcturus Therapeutics18028.42 million23.36 millionOptionableATHEAlterity Therapeutics108.87 million5.43 millionNot OptionableOKUROnKure TherapeuticsN/A40.40 million39.52 millionN/ATNXPTonix Pharmaceuticals5015.94 million15.62 millionNot OptionableATHE, TNXP, ARCT, and OKUR HeadlinesRecent News About These CompaniesTonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026July 27 at 8:46 AM | finance.yahoo.comTonix Pharmaceuticals Holding Corp. to Host Second Quarter 2026 Financial Results Conference Call and WebcastJuly 27 at 7:30 AM | quiverquant.comQTonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026July 27 at 7:00 AM | globenewswire.comTonix Pharma announces upcoming retirement of chief medical officerJuly 21, 2026 | tipranks.comTonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal ModelsJuly 15, 2026 | finance.yahoo.comTonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal ModelsJuly 15, 2026 | globenewswire.comTonix Expands TONMYA Medicare Coverage with New Payer Agreement (TNXP)July 13, 2026 | investorshub.advfn.comTonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®July 13, 2026 | finance.yahoo.comTonix Pharmaceuticals Announces Major Medicare Coverage Agreement for TONMYA, Expanding U.S. Access to Approximately 145 Million Covered LivesJuly 13, 2026 | quiverquant.comQTonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®July 13, 2026 | globenewswire.comTonix Pharmaceuticals Holding Corp (TNXP) Stock Price, Quote, News & HistoryJuly 10, 2026 | benzinga.comTonix Pharmaceuticals Holding Corp. (TNXP) Stock Price, News, Quote & History - Yahoo FinanceJuly 2, 2026 | finance.yahoo.comTonix: Slow Start For Tonmya, Speculative Pipeline Warrants Hold RatingJune 29, 2026 | seekingalpha.comTonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)June 29, 2026 | finance.yahoo.comTonix Pharma Begins Pivotal Phase 2 Depression TrialJune 29, 2026 | tipranks.comTonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)June 29, 2026 | globenewswire.comThis Tonix Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For ThursdayJune 25, 2026 | benzinga.comTonix Pharmaceuticals (NASDAQ:TNXP) Director Carolyn Taylor Purchases 1,415 SharesJune 16, 2026 | insidertrades.comWe're Keeping An Eye On Tonix Pharmaceuticals Holding's (NASDAQ:TNXP) Cash Burn RateJune 13, 2026 | finance.yahoo.comTonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026June 11, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 2026CEOs Sell Millions Worth of These 3 Big Name Stocks—What It Means for InvestorsBy Leo Miller | July 14, 2026Intel Earnings Reveal Whether the Chip Selloff Created a BuyBy Chris Markoch | July 24, 2026Travelers Stock Surges 10% as Earnings Beat Reveals Underwriting DisciplineBy Jeffrey Neal Johnson | July 21, 2026Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy StoryBy Chris Markoch | July 28, 2026ATHE, TNXP, ARCT, and OKUR Company DescriptionsArcturus Therapeutics NASDAQ:ARCT$5.76 -0.04 (-0.60%) As of 12:19 PM Eastern This is a fair market value price provided by Massive. Learn more.Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Alterity Therapeutics NASDAQ:ATHE$4.49 +0.05 (+1.01%) As of 11:59 AM Eastern This is a fair market value price provided by Massive. Learn more.Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.OnKure Therapeutics NASDAQ:OKUR$3.96 +0.01 (+0.13%) As of 12:19 PM Eastern This is a fair market value price provided by Massive. Learn more.OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.Tonix Pharmaceuticals NASDAQ:TNXP$9.85 +0.34 (+3.62%) As of 12:20 PM Eastern This is a fair market value price provided by Massive. Learn more.Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Powering Up: NextEra and Brookfield Build an Off-Grid Empire 2 Unique Space ETFs That Could Upend the Industry DoorDash's Drone Certification Could Reshape Its Delivery Margins Why NXP Semiconductors Could Be the AI Stock Everyone Is Missing Palantir’s Earnings Setup Puts Its AI Growth Story Back on Trial Again Circle’s IBM Patent Deal Could Redraw the Stablecoin Infrastructure Race Why SK hynix Could Be the Best AI Chip Stock to Buy Now Why Bloom Energy May Be the Most Important AI Infrastructure Stock Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
